Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded to “Strong-Buy” at Zacks Research

Zacks Research upgraded shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) from a hold rating to a strong-buy rating in a research report sent to investors on Wednesday morning,Zacks.com reports.

Several other brokerages also recently commented on KNSA. Jefferies Financial Group increased their price target on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, June 8th. Canaccord Genuity Group raised their target price on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Wedbush lifted their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a report on Wednesday, April 29th. Finally, Wells Fargo & Company boosted their target price on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. According to MarketBeat.com, Kiniksa Pharmaceuticals International presently has an average rating of “Buy” and an average price target of $60.86.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ:KNSA opened at $55.11 on Wednesday. The stock has a market capitalization of $4.24 billion, a P/E ratio of 61.23 and a beta of 0.12. The business has a 50-day moving average of $50.86 and a two-hundred day moving average of $46.27. Kiniksa Pharmaceuticals International has a fifty-two week low of $26.27 and a fifty-two week high of $59.87.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The business had revenue of $214.27 million for the quarter, compared to analyst estimates of $206.11 million. During the same quarter in the prior year, the firm posted $0.11 EPS. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. As a group, research analysts expect that Kiniksa Pharmaceuticals International will post 1.24 EPS for the current fiscal year.

Insider Buying and Selling

In other news, COO Ross Moat sold 2,367 shares of the firm’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $48.58, for a total value of $114,988.86. Following the sale, the chief operating officer owned 12,029 shares in the company, valued at approximately $584,368.82. This trade represents a 16.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the transaction, the insider directly owned 65,623 shares in the company, valued at $3,524,611.33. This trade represents a 47.10% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is currently owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of hedge funds have recently bought and sold shares of KNSA. Qube Research & Technologies Ltd lifted its stake in shares of Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares during the period. Rubric Capital Management LP increased its stake in Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after acquiring an additional 526,567 shares during the period. Bank of America Corp DE raised its holdings in Kiniksa Pharmaceuticals International by 220.9% in the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after acquiring an additional 506,576 shares in the last quarter. Cubist Systematic Strategies LLC raised its holdings in Kiniksa Pharmaceuticals International by 213.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock valued at $18,192,000 after acquiring an additional 447,536 shares in the last quarter. Finally, Spruce Street Capital LP bought a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth approximately $17,943,000. 53.95% of the stock is owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.